{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:20:08Z","timestamp":1747156808899,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cardfail.2024.04.026","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:37:27Z","timestamp":1716305847000},"page":"1108-1110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transthyretin Cardiac Amyloidosis: Increasing Evidence of the Benefits of A TTRansformation in Diagnostic and Treatment Strategies"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-5454","authenticated-orcid":false,"given":"JOBAN D.","family":"VAISHNAV","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FAROOQ H.","family":"SHEIKH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2024.04.026_bib0001","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0003","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0004","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0005","doi-asserted-by":"crossref","unstructured":"Huda A, Casta\u00f1o A, Niyogi A, Schumacher J, Stewart M, Bruno M, et al. A machine-learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. 2021;12:2725.","DOI":"10.1038\/s41467-021-22876-9"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0006","doi-asserted-by":"crossref","unstructured":"Casta\u00f1o A, Heitner SB, Masri A, Huda A, Calambur V, Bruno M, et al. EstimATTR: a simplified, machine-learning-based tool to predict the risk of wild-type transthyretin amyloid cardiomyopathy. J Card Fail 2023;7:S1071-9164(23)00895-3. https:\/\/doi.org\/10.1016\/j.cardfail.2023.11.017. Epub ahead of print. PMID: 38065306.","DOI":"10.1016\/j.cardfail.2023.11.017"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0007","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer M","year":"2019","journal-title":"Circulation: Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0008","first-page":"537","article-title":"Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the Transthyretin Amyloidosis Outcomes survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older Black patients with heart failure: the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0010","first-page":"2042","article-title":"False-positive 99mTc-pyrophosphate scanning leading to inappropriate tafamidis prescriptions","volume":"14","author":"Poterucha T","year":"2021","journal-title":"JACC: Cardiovasc Imag"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0011","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC Review Topic of the Week","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0012","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0013","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0014","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0015","doi-asserted-by":"crossref","unstructured":"Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al. Stratifying disease progression in patients with cardiac ATTR amyloidosis. 2024;83:1276\u201391.","DOI":"10.1016\/j.jacc.2023.12.036"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore J","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.04.026_bib0018","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424001842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424001842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T21:31:23Z","timestamp":1726608683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916424001842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1071916424001842"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.04.026","relation":{},"ISSN":["1071-9164"],"issn-type":[{"type":"print","value":"1071-9164"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin Cardiac Amyloidosis: Increasing Evidence of the Benefits of A TTRansformation in Diagnostic and Treatment Strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.02.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}